CompaniesInterveXion Therapeutics

InterveXion Therapeutics

active
Little Rock, AR, United States
Founded 2004
Website
About

Meth vaccine

Areas of Focus

Categories

VaccineSoutheastern U.S.
Clinical Trials (5)
View all

Total Trials

5

As Lead Sponsor

5

As Collaborator

0

Total Enrollment

209

By Phase

PHASE2: 2PHASE1: 2PHASE1/PHASE2: 1

By Status

COMPLETED: 3TERMINATED: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
NCT03336866
Hover over trial bars to see details

Recent Trials

NCT05034874Lead Sponsor
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
PHASE2Terminated
61 participants
Started: Jun 9, 2022 · Completed: Nov 7, 2023
NCT05027451Lead Sponsor
Safety, Tolerability, and Pharmacokinetics of IXT-m200
PHASE1Completed
9 participants
Started: Oct 25, 2021 · Completed: Mar 18, 2022
NCT04715230Lead Sponsor
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
PHASE2Terminated
20 participants
Started: Jun 30, 2021 · Completed: Nov 14, 2022
NCT03336866Lead Sponsor
Study of Antibody for Methamphetamine Outpatient Therapy
PHASE1/PHASE2Completed
77 participants
Started: May 3, 2018 · Completed: Mar 9, 2021
NCT01603147Lead Sponsor
Safety Study of Ch-mAb7F9 for Methamphetamine Abuse
PHASE1Completed
42 participants
Started: Apr 30, 2012 · Completed: Jul 31, 2013
Locations (1)
Headquarters
Little Rock, AR, United States
Map

Loading map...